---
title: "Bio Green Med Solution (BGMS) news: convertible notes and merger"
url: "https://aibio.space/companies/bio-green-med-solution/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "BGMS convertible notes and merger news: Preferred stock removed from Nasdaq as Bio Green Med reports first-quarter results. Bio Green Med Solution, Inc."
---

BGMS Bio Green Med Solution, Inc. NASDAQ · Malaysia

# Bio Green Med Solution (BGMS) news BGMS convertible notes and merger news

Mergers · 2026-08-12

## [Bio Green Med reports second-quarter results and updates Future NRG deal](https://aibio.space/news/bio-green-med-reports-second-quarter-results-updates-future-nrg-deal/)

Net loss was $0.4 million for the quarter ended June 30, 2026, while the company advances a share exchange that would make Future NRG Sdn. Bhd. a wholly owned subsidiary.

## Latest Bio Green Med Solution news

1. 2026-06-10 Financings [Bio Green Med sells 1,103,338 shares to foreign investors for $794,403](https://aibio.space/news/bio-green-med-sells-1-103-338-shares-foreign-investors-794-403/) The sale at $0.72 per share closed on June 10, 2026 under Regulation S, and the filing names no underwriter, placement agent or financial advisor.
2. 2026-06-04 Mergers [Bio Green Med agrees to all-stock deal to acquire Future NRG](https://aibio.space/news/bio-green-med-agrees-all-stock-deal-acquire-future-nrg/) A Business Combination Agreement would make Future NRG Sdn. Bhd., a Malaysian medical waste treatment company, a wholly owned subsidiary of Bio Green Med Solution, with closing expected in the fourth quarter of 2026.
3. 2026-05-14 Listings [Preferred stock removed from Nasdaq as Bio Green Med reports first-quarter results](https://aibio.space/news/preferred-stock-removed-nasdaq-bio-green-med-reports-first-quarter/) The 6% Convertible Exchangeable Preferred Stock, under the symbol BGMSP, stopped trading in March. The common stock, BGMS, remains listed, and first-quarter product revenue was $0.8 million.
4. 2025-09-16 Listings [Bio Green Med Solution preferred stock falls short of Nasdaq $1 million value rule](https://aibio.space/news/bio-green-med-solution-preferred-stock-falls-short-nasdaq-1-million/) Nasdaq says the 6% Convertible Exchangeable Preferred Stock has been below the $1 million minimum for publicly held shares for 30 consecutive business days. The company has until March 10, 2026 to regain compliance, and its 8-K does not say how it will get there.
5. 2025-09-04 Financings [Cyclacel (now Bio Green Med Solution) swaps Series C warrants for 559,395 shares](https://aibio.space/news/cyclacel-now-bio-green-med-solution-swaps-series-c-warrants-559-395/) Cyclacel Pharmaceuticals, now Bio Green Med Solution, agreed to exchange Series C warrants for 559,395 new common shares. The 8-K gives no exercise price and describes no cash payment.
6. 2025-03-31 Distress [Cyclacel (now Bio Green Med Solution) delays 2024 annual report](https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/) Cyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days.
7. 2025-01-06 Mergers [Cyclacel (now Bio Green Med Solution) agrees to sell $3.1 million of preferred stock](https://aibio.space/news/cyclacel-now-bio-green-med-solution-agrees-sell-3-1-million-preferred/) Investor David Lazar agreed to subscribe for $3.1 million of convertible preferred stock and become interim chief executive. A separate warrant exchange would issue 24,844,725 common shares and pay $1,100,000 in cash. The Series D closing and the warrant exchange need stockholder approval, and the Nasdaq deadline is February 6, 2025.

## Bio Green Med Solution at a glance

- **Ticker**: BGMS

- **Listing**: NASDAQ

- **Country**: Malaysia

- **Cash, Jun 30, 2026**: $3.8 million

### Related companies

- [Duopharma Biotech Bhd.](https://aibio.space/companies/duopharma-biotech/) MYX: DPHARMA
- [Y.S.P. Southeast Asia Holding Bhd.](https://aibio.space/companies/y-s-p-southeast-asia/) MYX: YSPSAH
- [Kotra Industries Bhd.](https://aibio.space/companies/kotra-industries/) MYX: KOTRA
- [Pharmaniaga Bhd.](https://aibio.space/companies/pharmaniaga/) MYX: PHARMA

### Also on NASDAQ

- [SeaStar Medical Holding](https://aibio.space/companies/seastar-medical/) ICU
- [Nexalin Technology](https://aibio.space/companies/nexalin-technology/) NXL
- [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ
- [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) BRVE
- [Phio Pharmaceuticals](https://aibio.space/companies/phio-pharmaceuticals/) PHIO
- [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) AXSM

## What Bio Green Med Solution does

Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., now specializes in the supply and trading of protective and fire safety equipment, with a focus on Malaysia's fire safety market and on commercial, industrial, healthcare and residential customers. The company says it has more than 30 years of experience in fire safety. The change followed several transactions. Its clinical research programs had been conducted through Cyclacel Limited, a subsidiary that entered creditors' voluntary liquidation, announced in the London Gazette on January 31, 2025. The company sold its patent rights for plogosertib (Plogo) to Tethra Biosciences Inc. for $300,000, plus a potential milestone payment of $170,000. The company closed a share exchange with FITTERS Diversified Berhad on September 12, 2025, under which Fitters Sdn. Bhd., a Malaysia-based company, became a wholly owned subsidiary. Product categories include fire extinguishers, foam systems, fire-resistant doors, personal protective equipment and fire safety apparel. The text says its products are approved by BOMBA and certified by SIRIM.

| Product or program | What it is | Stage |
|---|---|---|
| Fire extinguishers and foam systems | Fire-fighting equipment, including the FITTERS FIRE-X extinguisher and foam systems | Distributed; approved by BOMBA and certified by SIRIM |
| Fire-resistant doors | Fire-resistant doors supplied to customers | Offered as a product category |
| Personal protective equipment and fire safety apparel | Protective equipment and safety apparel for fire safety | Offered as a product category |

Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/form10-k.htm).

## Bio Green Med Solution annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) | [$43,000](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) |
| Research and development | [$848,000](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) |
| Net income (loss) | [-$3.0 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) |
| Cash from operations | [-$4.8 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) | [-$8.0 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) |
| Cash and equivalents | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226038393/) | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.8 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Bio Green Med Solution

Has Bio Green Med Solution sold convertible notes?

Our latest story on this, dated May 14, 2026: "Preferred stock removed from Nasdaq as Bio Green Med reports first-quarter results". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/preferred-stock-removed-nasdaq-bio-green-med-reports-first-quarter/).

Is Bio Green Med Solution involved in a merger or acquisition?

Our latest story on this, dated Jun 4, 2026: "Bio Green Med agrees to all-stock deal to acquire Future NRG". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bio-green-med-agrees-all-stock-deal-acquire-future-nrg/).

What is the ticker symbol of Bio Green Med Solution?

Bio Green Med Solution, Inc. trades under the ticker BGMS on NASDAQ.

Where is Bio Green Med Solution listed?

Bio Green Med Solution, Inc. is listed on NASDAQ. Our directory also records these other listings: OTC:BGMSP.

What is the SEC CIK of Bio Green Med Solution?

The SEC Central Index Key (CIK) for Bio Green Med Solution, Inc. is 1130166. Its filings are on SEC EDGAR.

How many shares does Bio Green Med Solution have outstanding?

6,622,794 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Bio Green Med Solution listed under?

Our directory records Bio Green Med Solution, Inc. under Malaysia.

What does Bio Green Med Solution do?

Our directory classifies Bio Green Med Solution, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Bio Green Med Solution?

The ISIN recorded for Bio Green Med Solution, Inc. is US23254L8761.

Does aibio.space cover Bio Green Med Solution?

aibio.space lists Bio Green Med Solution, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Bio Green Med Solution incorporated?

SEC records list its state or country of incorporation as DE.

What does Bio Green Med Solution develop?

Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., now specializes in the supply and trading of protective and fire safety equipment, with a focus on Malaysia's fire safety market and on commercial, industrial, healthcare and residential customers. The company says it has more than 30 years of experience in fire safety.

What is Fire extinguishers and foam systems from Bio Green Med Solution?

Fire extinguishers and foam systems: Fire-fighting equipment, including the FITTERS FIRE-X extinguisher and foam systems Stage: Distributed; approved by BOMBA and certified by SIRIM.

What is Fire-resistant doors from Bio Green Med Solution?

Fire-resistant doors: Fire-resistant doors supplied to customers Stage: Offered as a product category.

What was Bio Green Med Solution's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

## Investor discussion: Bio Green Med Solution

Members talk about Bio Green Med Solution (BGMS). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Bio Green Med Solution, newest first. Each line links the filing it comes from.

1. 2026-06-04 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315226027291/ex99-1.htm)
2. 2026-05-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315226023117/ex99-1.htm)
3. 2026-03-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315226009991/0001493152-26-009991-index-headers.html)
4. 2025-11-13 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315225022378/ex99-1.htm)
5. 2025-11-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315225020920/form8-k.htm)
6. 2025-10-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315225017223/form8-k.htm)
7. 2025-09-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315225013703/form8-k.htm)
8. 2025-09-12 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000149315225013123/ex99-1.htm)
9. 2025-09-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225026571/form8-k.htm)
10. 2025-08-28 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225025752/form8-k.htm)
11. 2025-08-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225023607/ex99-1.htm)
12. 2025-07-07 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225017914/form425.htm)
13. 2025-07-02 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225017479/ex99-1.htm)
14. 2025-06-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225013436/ex99-1.htm)
15. 2025-05-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000164117225008988/ex99-1.htm)
16. 2025-04-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000182912625002334/cyclacel_ex99-1.htm)
17. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1130166/000182912625002205/cyclacel_nt10k.htm)
18. 2025-03-14 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/cyclacel_8k.htm)
19. 2025-02-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,3.03,5.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000182912625001253/cyclacel_ex99-1.htm)
20. 2025-02-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000182912625001180/cyclacel_8k.htm)
21. 2025-02-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000182912625000765/cyclacel_8k.htm)
22. 2025-01-21 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1130166/000110465925004635/tm252001-3_def14a.htm)
23. 2025-01-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000110465925002198/tm252869d1_8k.htm)
24. 2025-01-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1130166/000110465925001821/tm252001-1_pre14a.htm)
25. 2025-01-06 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,3.03,5.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000110465925001087/tm251961d1_ex99-1.htm)
26. 2024-12-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000110465924128022/tm2430847d1_8k.htm)
27. 2024-11-12 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1130166/000110465924116875/tm2428051d1_8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BGMS on TradingView](https://www.tradingview.com/symbols/NASDAQ-BGMS/).

## SEC filings and registration

- **SEC name**: Bio Green Med Solution, Inc.

- **CIK**: 1130166

- **Industry (SIC)**: Wholesale-Durable Goods, NEC (5099)

- **US tickers**: BGMS (Nasdaq), BGMSP (OTC)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922

- **Phone**: 908-517-7330

- **Shares outstanding**: 6,622,794 as of 2026-08-11 (10-Q filed 2026-08-14)

- **Former names**: Cyclacel Pharmaceuticals, Inc.; XCYTE THERAPIES INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1130166/000149315226047396/form8-k.htm) filed 2026-10-16
- [10-Q](https://www.sec.gov/Archives/edgar/data/1130166/000149315226038393/form10-q.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1130166/000149315226037902/form8-k.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1130166/000149315226031542/form8-k.htm) filed 2026-07-01
- [8-K](https://www.sec.gov/Archives/edgar/data/1130166/000149315226029452/form8-k.htm) filed 2026-06-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1130166/000149315226028072/form8-k.htm) filed 2026-06-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1130166/000149315226027291/form8-k.htm) filed 2026-06-04
- [10-Q](https://www.sec.gov/Archives/edgar/data/1130166/000149315226023800/form10-q.htm) filed 2026-05-15

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001130166), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Bio Green Med Solution, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BGMS, recorded under Malaysia. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Bio Green Med Solution, Inc.

- **Ticker**: BGMS

- **Listing**: NASDAQ

- **Country or territory**: Malaysia

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US23254L8761

- **Other listed symbols**: OTC:BGMSP

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BGMS/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/bio-green-med-solution/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bio Green Med Solution (BGMS) news: convertible notes and merger", 2026-10-31, https://aibio.space/companies/bio-green-med-solution/